Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.
2.

PDE11A negatively regulates lithium responsivity.

Pathak G, Agostino MJ, Bishara K, Capell WR, Fisher JL, Hegde S, Ibrahim BA, Pilarzyk K, Sabin C, Tuczkewycz T, Wilson S, Kelly MP.

Mol Psychiatry. 2017 Dec;22(12):1714-1724. doi: 10.1038/mp.2016.155. Epub 2016 Sep 20.

3.

TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics.

Gupta M, Neavin D, Liu D, Biernacka J, Hall-Flavin D, Bobo WV, Frye MA, Skime M, Jenkins GD, Batzler A, Kalari K, Matson W, Bhasin SS, Zhu H, Mushiroda T, Nakamura Y, Kubo M, Wang L, Kaddurah-Daouk R, Weinshilboum RM.

Mol Psychiatry. 2016 Dec;21(12):1717-1725. doi: 10.1038/mp.2016.6. Epub 2016 Feb 23.

4.

A genome-wide association study of antidepressant response in Koreans.

Myung W, Kim J, Lim SW, Shim S, Won HH, Kim S, Kim S, Lee MS, Chang HS, Kim JW, Carroll BJ, Kim DK.

Transl Psychiatry. 2015 Sep 8;5:e633. doi: 10.1038/tp.2015.127. Erratum in: Transl Psychiatry. 2015;5:e672.

5.

Association of FKBP51 with priming of autophagy pathways and mediation of antidepressant treatment response: evidence in cells, mice, and humans.

Gassen NC, Hartmann J, Zschocke J, Stepan J, Hafner K, Zellner A, Kirmeier T, Kollmannsberger L, Wagner KV, Dedic N, Balsevich G, Deussing JM, Kloiber S, Lucae S, Holsboer F, Eder M, Uhr M, Ising M, Schmidt MV, Rein T.

PLoS Med. 2014 Nov 11;11(11):e1001755. doi: 10.1371/journal.pmed.1001755. eCollection 2014 Nov.

6.

Genetic prediction of antidepressant drug response and nonresponse in Korean patients.

Lim SW, Won HH, Kim H, Myung W, Kim S, Kim KK, Carroll BJ, Kim JW, Kim DK.

PLoS One. 2014 Sep 16;9(9):e107098. doi: 10.1371/journal.pone.0107098. eCollection 2014.

7.

The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.

Tomita T, Yasui-Furukori N, Nakagami T, Tsuchimine S, Ishioka M, Kaneda A, Sugawara N, Kaneko S.

PLoS One. 2014 May 23;9(5):e98099. doi: 10.1371/journal.pone.0098099. eCollection 2014.

8.

Influence of RGS2 on sertraline treatment for social anxiety disorder.

Stein MB, Keshaviah A, Haddad SA, Van Ameringen M, Simon NM, Pollack MH, Smoller JW.

Neuropsychopharmacology. 2014 May;39(6):1340-6. doi: 10.1038/npp.2013.301. Epub 2013 Oct 24.

9.

Race, genetic ancestry and response to antidepressant treatment for major depression.

Murphy E, Hou L, Maher BS, Woldehawariat G, Kassem L, Akula N, Laje G, McMahon FJ.

Neuropsychopharmacology. 2013 Dec;38(13):2598-606. doi: 10.1038/npp.2013.166. Epub 2013 Jul 5.

10.

A genome-wide association study of a sustained pattern of antidepressant response.

Hunter AM, Leuchter AF, Power RA, Muthén B, McGrath PJ, Lewis CM, Cook IA, Garriock HA, McGuffin P, Uher R, Hamilton SP.

J Psychiatr Res. 2013 Sep;47(9):1157-65. doi: 10.1016/j.jpsychires.2013.05.002. Epub 2013 May 30.

11.

Revisiting serotonin reuptake inhibitors and the therapeutic potential of "uptake-2" in psychiatric disorders.

Daws LC, Koek W, Mitchell NC.

ACS Chem Neurosci. 2013 Jan 16;4(1):16-21. doi: 10.1021/cn3001872.

12.

Effect of obstructive sleep apnea on response to cognitive behavior therapy for depression after an acute myocardial infarction.

Freedland KE, Carney RM, Hayano J, Steinmeyer BC, Reese RL, Roest AM.

J Psychosom Res. 2012 Apr;72(4):276-81. doi: 10.1016/j.jpsychores.2011.12.012. Epub 2012 Jan 28.

13.

Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses.

Gueorguieva R, Mallinckrodt C, Krystal JH.

Arch Gen Psychiatry. 2011 Dec;68(12):1227-37. doi: 10.1001/archgenpsychiatry.2011.132.

14.

FKBP51 and FKBP52 in signaling and disease.

Storer CL, Dickey CA, Galigniana MD, Rein T, Cox MB.

Trends Endocrinol Metab. 2011 Dec;22(12):481-90. doi: 10.1016/j.tem.2011.08.001. Epub 2011 Aug 31. Review.

15.

Biomarkers in development of psychotropic drugs.

Wiedemann K.

Dialogues Clin Neurosci. 2011;13(2):225-34. Review.

16.

Functional biomarkers of depression: diagnosis, treatment, and pathophysiology.

Schmidt HD, Shelton RC, Duman RS.

Neuropsychopharmacology. 2011 Nov;36(12):2375-94. doi: 10.1038/npp.2011.151. Epub 2011 Aug 3. Review.

17.

Pharmacogenetics of antidepressants.

Crisafulli C, Fabbri C, Porcelli S, Drago A, Spina E, De Ronchi D, Serretti A.

Front Pharmacol. 2011 Feb 16;2:6. doi: 10.3389/fphar.2011.00006. eCollection 2011.

18.

PharmGKB summary: citalopram pharmacokinetics pathway.

Sangkuhl K, Klein TE, Altman RB.

Pharmacogenet Genomics. 2011 Nov;21(11):769-72. doi: 10.1097/FPC.0b013e328346063f. Review. No abstract available.

19.

Pharmacogenetics of antidepressant response.

Porcelli S, Drago A, Fabbri C, Gibiino S, Calati R, Serretti A.

J Psychiatry Neurosci. 2011 Mar;36(2):87-113. doi: 10.1503/jpn.100059. Review.

20.

Genome-wide association studies of antidepressant outcome: a brief review.

Laje G, McMahon FJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1553-7. doi: 10.1016/j.pnpbp.2010.11.031. Epub 2010 Nov 27. Review.

Supplemental Content

Support Center